Investor Overview

Overview

Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

SEC Filings

Filing date Description Form View

An amendment to a SC 13D filing

SC 13D/A View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.